interleukin-8 has been researched along with Lewy-Body-Disease* in 2 studies
1 review(s) available for interleukin-8 and Lewy-Body-Disease
Article | Year |
---|---|
Cerebrospinal Fluid Concentrations of the Synaptic Marker Neurogranin in Neuro-HIV and Other Neurological Disorders.
The aim of this study was to examine the synaptic biomarker neurogranin in cerebrospinal fluid (CSF) in different stages of HIV infection and in relation to what is known about CSF neurogranin in other neurodegenerative diseases.. CSF concentrations of neurogranin are increased in Alzheimer's disease, but not in other neurodegenerative disorder such as Parkinson's disease, frontotemporal dementia, and Lewy body dementia. Adults with HIV-associated dementia have been found to have decreased levels of neurogranin in the frontal cortex, which at least to some extent, may be mediated by the proinflammatory cytokines IL-1β and IL-8. CSF neurogranin concentrations were in the same range for all groups of HIV-infected individuals and uninfected controls. This either indicates that synaptic injury is not an important part of HIV neuropathogenesis or that CSF neurogranin is not sensitive to the type of synaptic impairment present in HIV-associated neurocognitive disorders. Topics: Adult; AIDS Dementia Complex; Alzheimer Disease; Biomarkers; Female; Frontal Lobe; Frontotemporal Dementia; HIV Infections; Humans; Interleukin-1beta; Interleukin-8; Lewy Body Disease; Male; Middle Aged; Neurogranin; Parkinson Disease | 2019 |
1 other study(ies) available for interleukin-8 and Lewy-Body-Disease
Article | Year |
---|---|
Peripheral inflammation in prodromal Alzheimer's and Lewy body dementias.
There is growing evidence for the role of systemic inflammation in Alzheimer's disease (AD) and other neurodegenerative diseases; however the systemic inflammatory profile in dementia with Lewy bodies (DLB) has never before been investigated. This study aimed to characterise systemic inflammatory mediators in established DLB and AD, as well as in their prodromal, mild cognitive impairment (MCI) phases.. We obtained plasma samples from patients with DLB (n=37), AD (n=20), MCI with DLB profile (n=38), MCI with AD profile (n=20) and healthy control subjects (n=20). The following inflammatory biomarkers were measured using Roche cobas c702 and Meso Scale Discovery V-Plex Plus: high-sensitivity C-reactive protein, interferon-gamma, interleukin (IL)-10, IL-12p70, IL-13, IL-1beta, IL-2, IL-4, IL-6, IL-8 and tumour necrosis factor-alpha.. We found significantly higher levels of IL-10, IL-1beta, IL-4 and IL-2 in both MCI groups (P<0.001), while there was no significant difference in inflammatory markers between dementia groups and controls. Furthermore, increased disease severity was associated with lower levels of IL-1beta, IL-2 and IL-4 (P<0.05).. We have shown for the first time that in both DLB and AD, increased peripheral inflammation occurs early at the MCI disease stages. These data support a role for inflammation early in the disease process, and have important implications for the stage of disease where trials of anti-inflammatory medication should be focused. Topics: Aged; Aged, 80 and over; Alzheimer Disease; C-Reactive Protein; Case-Control Studies; Cognitive Dysfunction; Cytokines; Female; Humans; Inflammation; Interferon-gamma; Interleukin-10; Interleukin-12; Interleukin-13; Interleukin-1beta; Interleukin-2; Interleukin-4; Interleukin-6; Interleukin-8; Lewy Body Disease; Male; Prodromal Symptoms; Tumor Necrosis Factor-alpha | 2018 |